MedTrace Logo

A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation

NCT00154843 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2008-01-14

No results posted yet for this study

Summary

Primary: To determine factors that affect absorption and serum levels of lycopene after supplementation.

Secondary:

1. To evaluate general safety and tolerability of oral lycopene 15 or 30 mg per day for 12 weeks.
2. To determine lycopene effects on reducing serum levels of prostate specific antigen (PSA) and on relieving lower urinary tract symptoms (LUTS) in relation to prostate hypertrophy as evaluated by the International Prostate Symptom Score (I-PSS).

Conditions

  • BPH

Interventions

DRUG

Lycopene

A: Lycopene15 mg/day ; B: Lycopene30 mg/day

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yeong-Shiau Pu, MD, PhD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154843 on ClinicalTrials.gov